Trane Technologies plc (TT)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 325.89 |
| Open | 326.89 |
| Bid | 0.00 x 800 |
| Ask | 524.16 x 800 |
| Day's range | 325.10 - 329.14 |
| 52-week range | 162.04 - 329.14 |
| Volume | |
| Avg. volume | 955,496 |
| Market cap | 74.153B |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | 34.59 |
| EPS (TTM) | 9.47 |
| Earnings date | 02 Aug 2024 - 17 Aug 2024 |
| Forward dividend & yield | 3.36 (1.03%) |
| Ex-dividend date | 07 Jun 2024 |
| 1y target est | N/A |
FX EmpireTrane Technologies Shares Heating Up on Big Money Buys
Trane Technologies plc (TT) shares are up 34% this year. It’s clear why the heating and cooling company is rising – Big Money investors have been buying the stock for a while.
ZacksAvis Budget (CAR) Gains 28% Despite Earnings Miss in Q1
Avis Budget (CAR) witnesses a y/y decline in revenues from the Americas, while international revenues increase.
PR NewswireAcepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).
© 2024 Yahoo. All rights reserved.